Orasis gains FDA approval for presbyopia eye drops, following in AbbVie’s footsteps

2023-10-18

临床3期上市批准申请上市

Orasis Pharmaceuticals has secured approval in the US for its age-related blurry vision eye drops, marking the second time the FDA has greenlit a presbyopia treatment. The OK for Qlosi comes a few days ahead of the FDA decision deadline, which is Sunday. The eye drops, which can be dosed up to twice daily, will become available in the first half of next year, Orasis said. AbbVie snagged the first FDA clearance for blurry vision eye drops in 2021, with Vuity, but the Chicago-area Big Pharma took a $770 million pre-tax impairment charge last fall when it decided to pull back on its big sales and marketing spend . The pharma giant then axed a second-generation presbyopia asset, Endpoints News reported earlier this year. Meanwhile, other companies have candidates in Phase III, including Viatris-partnered Ocuphire Pharma, Lenz Therapeutics and Visus Therapeutics , which plans to file an NDA in the second half of 2024, pending results from another trial slated to read out later this year.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构